Home › Compare › SKPGF vs ABBV
SKPGF yields 322.74% · ABBV yields 3.06%● Live data
📍 SKPGF pulled ahead of the other in Year 1
Combined, SKPGF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of SKPGF + ABBV for your $10,000?
Spark Power Group Inc. provides electrical power services and solutions in North America. The company operates through Technical Services, Renewables, and Sustainability Solutions segments. The Technical Services segment offers low-voltage technical services, including electrical contracting, custom control panel design and assembly, industrial automation, electronic repair, systems integration, and 24/7 emergency services; and medium and high voltage technical services, such as power 'on', equipment installation, sub-station construction and maintenance, commissioning, power line construction and maintenance, thermography, and transformer maintenance services. It also provides engineering services comprising power systems engineering, protection and control engineering, substation engineering, SCADA engineering, and arc flash studies, as well as fabrication shop/paint services; buys, refurbishes, and resales used electrical equipment; sells and rents power transformers; and sells medium voltage electrical switchgears. The Renewables segment offers renewables operations and maintenance services focused on wind, solar, battery energy storage systems, and electric vehicle assets. The Sustainability Solutions segment provides renewable energy credit, power purchase agreements, and various energy efficiency services, as well as renewable energy procurement and carbon footprint reduction services. The company serves approximately 6,500 industrial, commercial, institutional, renewable, and agricultural customers, as well as utility markets, including municipalities, universities, schools, and hospitals. Spark Power Group Inc. is headquartered in Oakville, Canada.
Full SKPGF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.